Cancer drug trial halted early: what happened with AB-106?
NCT ID NCT04617054
First seen Jan 21, 2026 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tested a daily pill called AB-106 in people with advanced solid tumors that have a specific gene change (NTRK fusion). The goal was to see if the drug could shrink tumors. Only 14 people took part before the study was stopped early. The drug was given until the cancer got worse or side effects became too severe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.